FDA

Scholar argues that Congress and FDA should treat risky clinical artificial intelligence tools as medical devices.

FDA’s approach to evidence-based decision-making may not be addressed to the right people.

Experts contend that FDA clinical trials fail to ensure adequate consideration of women’s health needs.

Exploring FDA’s toolkit for encouraging study sponsors to meet diversity goals.

Scholar highlights the fragmented regulatory environment governing advanced neurological technology.

Two scholars find that the removal of FDA health warnings prompts an increase in drug marketing.

Scholars explore regulatory approaches to artificial intelligence in the health care sector.

The CDC should recommend agricultural reforms to reduce pandemic risks caused by factory farms.

Despite delayed government action, manufacturers can do more to reduce toxic metals in baby food.

Scholars consider how the authorization of telehealth can expand access to medication abortion.

In this week’s Saturday Seminar, we collect scholarship discussing quality and safety issues within U.S. food regulation.

Insurance underwriters can help farmers manage the risk of microbial contamination in their fields.